ERBB2 and glioma: Indeed, Ahmed et al. tested the safety of intravenous injection of virus-specific (VS) CAR-T cells directed to HER-2 in a phase I clinical trial on patients affected by high grade gliomas: with 17 patients treated, including 7 children <18 years, the approach resulted to be safe, without any dose-limiting toxicity (DLT) reported (21).